0000000000568172

AUTHOR

Giulia Gioia

showing 1 related works from this author

Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicen…

2017

SummaryBackground Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal. Aim To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV-cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence. Methods We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web-based RESIST-HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the…

Liver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaEarly RecurrenceDIRECT ACTING ANTIVIRALSAntiviral AgentsGastroenterologyhepatocellular carcinoma (HCC)03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineClinical endpointCarcinomaHumansPharmacology (medical)Prospective StudiesProspective cohort studyneoplasmsComplete responseAgedhepatocellular carcinoma (HCC) HCV directacting antivirals (DAAs)Settore MED/12 - GastroenterologiaSettore MED/08 - ANATOMIA PATOLOGICAHepatologybusiness.industrydirectacting antivirals (DAAs)Liver NeoplasmsCarcinomaGastroenterologyCancerHepatocellularMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesNeoplasm RecurrenceLocal030220 oncology & carcinogenesisHepatocellular carcinomaHCVCatheter AblationFemale030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct